share_log

復星醫藥：海外監管公告 - 2024年第一季度報告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 29 18:29
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年4月29日發布2024年第一季度報告。報告顯示，該季度復星醫藥實現營業收入約101.57億元，同比下降6.56%。归属于上市公司股东的净利润約為6.10億元，同比大幅下降38.22%。基本每股收益為0.23元，較去年同期下降37.84%。報告期內，復星醫藥的經營活動產生的現金流量净额為9.17億元，同比增長5.05%。公司董事會及全體董事保證報告內容真實、準確、完整，並承擔法律責任。復星醫藥表示，營業收入下降主要是由於2023年第一季度新冠相關產品的銷售貢獻，而2024年同期該等產品收入同比大幅下降所致。不過，報告期內部分重點品種收入保持快速增長。此外，公司持續推進創新轉型和產品開發，並在報告期內取得多項產品進展。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年4月29日發布2024年第一季度報告。報告顯示，該季度復星醫藥實現營業收入約101.57億元，同比下降6.56%。归属于上市公司股东的净利润約為6.10億元，同比大幅下降38.22%。基本每股收益為0.23元，較去年同期下降37.84%。報告期內，復星醫藥的經營活動產生的現金流量净额為9.17億元，同比增長5.05%。公司董事會及全體董事保證報告內容真實、準確、完整，並承擔法律責任。復星醫藥表示，營業收入下降主要是由於2023年第一季度新冠相關產品的銷售貢獻，而2024年同期該等產品收入同比大幅下降所致。不過，報告期內部分重點品種收入保持快速增長。此外，公司持續推進創新轉型和產品開發，並在報告期內取得多項產品進展。
SHANGHAI FUXING PHARMACEUTICALS (GROUP) CO., LTD. (“FUXING PHARMACEUTICALS”) ISSUED ITS FIRST QUARTER REPORT FOR 2024 ON 29 APRIL 2024. The report showed that Pustar Pharmaceuticals achieved sales revenue of approximately $101.57 billion in the quarter, down 6.56% year-on-year. Net profit attributable to shareholders of listed companies was approximately $6.10 billion, down by 38.22% year-on-year. Basic earnings per share were $0.23, down 37.84% from the same period last year. During the reporting period, the net cash flow generated by the operations of Fustar Pharmaceuticals was US$9.17 billion, an increase of 5.05% year-on-year. The Board of Directors of the Company and all Directors ensure that the content of the reports is truthful, accurate, complete and legally liable. FUSTAR PHARMACEUTICALS SAID THE DECLINE IN REVENUE WAS MAINLY...Show More
SHANGHAI FUXING PHARMACEUTICALS (GROUP) CO., LTD. (“FUXING PHARMACEUTICALS”) ISSUED ITS FIRST QUARTER REPORT FOR 2024 ON 29 APRIL 2024. The report showed that Pustar Pharmaceuticals achieved sales revenue of approximately $101.57 billion in the quarter, down 6.56% year-on-year. Net profit attributable to shareholders of listed companies was approximately $6.10 billion, down by 38.22% year-on-year. Basic earnings per share were $0.23, down 37.84% from the same period last year. During the reporting period, the net cash flow generated by the operations of Fustar Pharmaceuticals was US$9.17 billion, an increase of 5.05% year-on-year. The Board of Directors of the Company and all Directors ensure that the content of the reports is truthful, accurate, complete and legally liable. FUSTAR PHARMACEUTICALS SAID THE DECLINE IN REVENUE WAS MAINLY DUE TO SALES OF NEW CROWN-RELATED PRODUCTS IN THE FIRST QUARTER OF 2023, WHILE REVENUE FROM SUCH PRODUCTS FELL SIGNIFICANTLY YEAR-ON-YEAR FOR THE SAME PERIOD IN 2024. However, income in some key varieties continued to grow rapidly during the reporting period. In addition, the company continued to drive innovation transformation and product development, and achieved several product developments during the reporting period.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.